Literature DB >> 8814299

Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1.

Y Lamari1, C Boissard, M S Moukhtar, A Jullienne, G Rosselin, J M Garel.   

Abstract

We have characterized, by RT-PCR amplification using specific primers, the presence of glucagon-like peptide-1 (GLP-I) receptor mRNA in CA-77 cells, a C cell line derived from a rat medullary thyroid carcinoma. Down-regulation of the GLP-1 receptor mRNA was observed after exposure of CA-77 C cells with GLP-1 (7-37). Increased secretion of both calcitonin gene-related peptide (CGRP) and calcitonin (CT) occurred after treatment with GLP-1 (7-37) associated with elevated steady-state levels of CGRP and CT mRNA. GLP-1 (7-37) increased cAMP formation in CA-77 cells in a dose-dependent manner; exendin (9-39), a GLP-1 receptor antagonist, inhibited cAMP production. The GLP-1 peptide which is produced by intestinal cells could be involved in the control of CT secretion through an entero-thyroidal axis implying GLP-1 receptor and increased CT gene expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814299     DOI: 10.1016/0014-5793(96)00895-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Association of circulating dipeptidyl-peptidase 4 levels with osteoporotic fracture in postmenopausal women.

Authors:  H Kim; K H Baek; S-Y Lee; S H Ahn; S H Lee; J-M Koh; Y Rhee; C H Kim; D-Y Kim; M-I Kang; B-J Kim; Y-K Min
Journal:  Osteoporos Int       Date:  2016-11-19       Impact factor: 4.507

Review 2.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 3.  Should we still be concerned about the potential side effects of glucagon-like peptide-1 receptor agonists on thyroid C cells?

Authors:  Yang Cao; Xiao-Min Liu
Journal:  Endocrine       Date:  2014-07-18       Impact factor: 3.633

4.  Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

Authors:  Indu Poornima; Suzanne B Brown; Siva Bhashyam; Pratik Parikh; Hakki Bolukoglu; Richard P Shannon
Journal:  Circ Heart Fail       Date:  2008-09       Impact factor: 8.790

5.  Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.

Authors:  Chrysi Koliaki; John Doupis
Journal:  Diabetes Ther       Date:  2011-02-28       Impact factor: 2.945

Review 6.  A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.

Authors:  Wei-Yih Chiu; Shyang-Rong Shih; Chin-Hsiao Tseng
Journal:  Exp Diabetes Res       Date:  2012-05-28

Review 7.  The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?

Authors:  Ricardo Godinho; Cristina Mega; Edite Teixeira-de-Lemos; Eugénia Carvalho; Frederico Teixeira; Rosa Fernandes; Flávio Reis
Journal:  J Diabetes Res       Date:  2015-05-17       Impact factor: 4.011

8.  Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.

Authors:  Daniel J Drucker; Steven I Sherman; Fred S Gorelick; Richard M Bergenstal; Robert S Sherwin; John B Buse
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

9.  Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism.

Authors:  Elena Ceccarelli; Elisa G Guarino; Daniela Merlotti; Aurora Patti; Luigi Gennari; Ranuccio Nuti; Francesco Dotta
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-18       Impact factor: 5.555

10.  GLP-1 receptors in golden Syrian hamster islets: identification and functional characterization.

Authors:  G Rosselin; V Leclercq-Meyer; C Boissart; M Pessah; W J Malaisse
Journal:  Endocrine       Date:  1998-06       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.